Alterity Therapeutics Ltd has released a press release.
ATH434 protects brain cells and improves motor function
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity to present at Global Life Science Conference
- Michael J Fox grant for Parkinsons research on ATH434
- Alterity participates in JP Morgan healthcare conference
- Dr David Stamler Appointed CEO
- Form F-3
Later from Alterity Therapeutics
- EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
- New US patent targeting major neurodegenerative diseases
- New Publication Demonstrates ATH434 is Neuroprotective
- New US Patent Expands Neurodegeneration Treatment Portfolio
- Appendix 4E & Annual Report 2021
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics